Baricitinib is a once-daily oral Janus kinase (JAK) inhibitor. In the United States it is approved as Olumiant for adults with rheumatoid arthritis after a TNF blocker, for hospitalised adults with COVID-19 who need oxygen, and for severe alopecia areata.[1][3]
This page explains the medicine using official sources and lists 10 products as listed by their suppliers, plus the originator Olumiant. It is not a complete global list, and regulatory status differs by product and country.[5]
Availability enquiries are handled by Medicine for World. Submission of an enquiry does not confirm regulatory eligibility, supply or delivery. Ownership and commercial disclosure
Baricitinib is the international non-proprietary name of an oral Janus kinase (JAK) inhibitor. JAK enzymes pass on signals from several cytokines involved in inflammation and immune responses; baricitinib reduces this signalling.[1]
According to the current US prescribing information (DailyMed, revised June 2026), Olumiant is indicated for:[1]
In the European Union, where it was first authorised on 13 February 2017, Olumiant is authorised for rheumatoid arthritis in adults, moderate to severe atopic dermatitis in adults and children from 2 years, severe alopecia areata in adults and adolescents from 12 years, and juvenile idiopathic arthritis from 2 years. Approved uses differ between countries.[2]
Whether baricitinib is suitable, and at which dose, is decided by the treating physician. Full warnings are in the official product information:
The products below are included for identification and availability-enquiry purposes. Inclusion does not mean that a product is authorised, approved, therapeutically equivalent or available in every country. Confirm regulatory status with the relevant national medicines authority.
Products are listed in alphabetical order. The list is not a ranking and makes no claim that one product is better than another.[5]
No product matches these filters.
Product listing data last checked October 6, 2026.
Olumiant is the originator baricitinib medicine. Baricitinib was discovered by Incyte and licensed to Eli Lilly and Company in 2009. Olumiant was first authorised in the European Union on 13 February 2017 and in the United States in 2018. Olumiant itself is not part of the Medicine for World listing; its card links to the official US prescribing information. Other products represented as containing baricitinib are made by other manufacturers and sold under their own brand names.[1][2][4]
The originator is shown here separately from the other listed products.
This comparison covers identity and listing information only. It does not establish regulatory approval, pharmaceutical equivalence, bioequivalence, quality, safety or clinical effectiveness.
| Attribute | Other listed baricitinib products | Originator (Olumiant) |
|---|---|---|
| Active substance | Baricitinib, as listed. Formulation details are not stated in the product listings.[5] | Baricitinib[1] |
| Brand name | Each manufacturer's own brand name (10 products listed)[5] | Olumiant[1] |
| Company | 9 manufacturers, with manufacturing countries listed as Bangladesh or Laos[5] | Eli Lilly and Company[1] |
| Dosage form | Tablet, as listed[5] | Film-coated tablet[1] |
| Strengths | 2 mg and/or 4 mg, as listed[5] | 1 / 2 / 4 mg[1] |
| Regulatory approval | Varies by product and country. Not independently verified for this page; check with your national medicines authority. | EU 13 February 2017 · US 2018[2][1] |
| Classification | Product represented by its manufacturer or supplier as containing baricitinib. Regulatory classification must be confirmed in the relevant jurisdiction.[5] | Originator product[1] |
The information below summarises the US prescribing information. It is not complete; read the full label and talk to your doctor.[1]
| Side effect | Reported in |
|---|---|
| Upper respiratory tract infections (RA, 2 mg) | 16.3% (placebo 11.7%) |
| Nausea (RA, 2 mg) | 2.7% (placebo 1.6%) |
| Herpes zoster / shingles (RA, 2 mg) | 1.0% (placebo 0.4%) |
| Herpes simplex (RA, 2 mg) | 0.8% (placebo 0.7%) |
| Headache (alopecia areata, 4 mg) | 6.6% (placebo 5.4%) |
| Acne (alopecia areata, 4 mg) | 5.9% (placebo 2.2%) |
| Raised blood lipids (alopecia areata, 4 mg) | 5.9% (placebo 3.0%) |
Baricitinib is taken by mouth once a day, with or without food. Blood counts are checked first: in rheumatoid arthritis and alopecia areata it should not be started if haemoglobin is below 8 g/dL, lymphocytes below 500 cells/mm³ or neutrophils below 1000 cells/mm³. Your doctor decides the dose.[1]
| Use | Daily dose | Notes |
|---|---|---|
| Rheumatoid arthritis (adults) | 2 mg once daily | Alone or with methotrexate or other non-biologic DMARDs |
| COVID-19 (hospitalised adults) | 4 mg once daily | For up to 14 days or until hospital discharge, whichever comes first |
| Severe alopecia areata | 2 mg once daily | Increased to 4 mg if the response is not adequate; 4 mg can be considered for nearly complete or complete scalp hair loss; reduced to 2 mg once the response is adequate |
| Rheumatoid arthritis with eGFR 30 to under 60 | 1 mg once daily | Not recommended if eGFR is below 30 |
The doses in the table are US label information, not a personal recommendation.[1]
Rheumatoid arthritis: in study RA-4 (527 adults after one or more TNF inhibitors), 49% on baricitinib 2 mg reached an ACR20 response at week 12, compared with 27% on placebo. In study RA-3 (684 adults after conventional DMARDs) the figures were 66% and 39%.[1]
COVID-19: in the COVID II trial (1,525 hospitalised adults), 8.1% died by day 28 with baricitinib 4 mg compared with 13.3% with placebo; the primary endpoint (death or progression to ventilation) was not statistically significant (27.8% vs 30.5%).[1]
Alopecia areata: at week 36, at least 80% scalp hair coverage (SALT ≤20) was reached by 35% and 32% of adults on 4 mg, 22% and 17% on 2 mg, and 5% and 3% on placebo in trials AA-1 and AA-2.[1] In adolescents (BRAVE-AA-PEDS) the figures were 42% (4 mg), 27% (2 mg) and 5% (placebo).[3]
Tell us your country and the product information you are looking for.
Medicine for World reviews destination-country restrictions and may request prescription or treatment documentation through a secure channel.
If the request can lawfully be supported, you may receive current product information, availability and a quotation.
Any transaction is subject to prescription requirements, supplier checks, local law, import rules and final confirmation.
Submitting an enquiry does not guarantee availability, regulatory eligibility, import permission, delivery or a transaction.
Submit a non-binding enquiry. Medicine for World will review the destination country and available options before requesting any sensitive medical documents.
This service cannot assist with medical emergencies or treatment decisions. Contact your treating healthcare professional or local emergency service.
Baricitinib is a prescription-only, once-daily oral JAK inhibitor. The originator brand is Olumiant by Eli Lilly and Company. It reduces signalling by JAK enzymes, which are involved in inflammation and immune responses.
In the US: adults with rheumatoid arthritis after a TNF blocker, hospitalised adults with COVID-19 who need oxygen, and severe alopecia areata (since September 2026 also from 12 years). In the EU: rheumatoid arthritis, atopic dermatitis, severe alopecia areata and juvenile idiopathic arthritis. Approved uses differ by country.
No. They are all oral JAK inhibitors, but they are different molecules with different approved uses and doses. The class warnings on mortality, cancer, heart events and blood clots in the US label come partly from a large study of another JAK inhibitor.
Upper respiratory tract infections, nausea, herpes zoster and herpes simplex in rheumatoid arthritis; headache, acne and raised blood lipids were also reported in alopecia areata. The label contains a boxed warning about serious infections, mortality, cancer, heart events and blood clots.
Yes. According to the US label it is taken once a day, with or without food.
10 products represented by their manufacturers or suppliers as containing baricitinib – Baricent, Baricinix, Barigen, Barinib, Barinib 2, Barinib-2, Baritor, Barudx, LuciBaric and Palutini – plus the originator Olumiant. It is not a complete global list, and inclusion does not mean that a product is authorised in any specific country.
This page does not establish that. Equivalence, quality and regulatory status depend on each product and each country and must be confirmed with the national medicines authority and your doctor.
Use the non-binding enquiry form on this page. Medicine for World reviews destination-country rules and may ask for a prescription before offering any option. Clicking a brand opens its product page on the Medicine for World website.
Current editorial and medical-review status is shown below. No independent medical review is claimed until it has been completed.
Medical and regulatory facts come from official product information. Product listing details come from a supplied dataset. Numbers in square brackets on this page refer to the sources below.